Navigation Links
New Finding Could Mark Shift in Alzheimer's Research

'Floating' clumps of protein, not plaques, may cause the disease, researchers say

THURSDAY, April 29 (HealthDay News) -- New research could change the way scientists view the causes -- and potential prevention and treatment -- of Alzheimer's disease.

A study published online this month in the Annals of Neurology suggests that "floating" clumps of amyloid beta (abeta) proteins called oligomers could be a prime cause of the disorder, and that the better-known and more stationary amyloid-beta plaques are only a late manifestation of the disease.

"Based on these and other studies, I think that one could now fairly revise the 'amyloid hypothesis' to the 'abeta oligomer hypothesis,'" said lead researcher Dr. Sam Gandy, a professor of neurology and psychiatry and associate director of the Alzheimer's Disease Research Center at Mount Sinai School of Medicine in New York City.

The new study could herald a major shift in Alzheimer's research, another expert said.

Maria Carrillo, senior director of medical and scientific relations at the Alzheimer's Association, said that "we are excited about the paper. We think it has some very interesting results and has potential for moving us in another direction for future research."

According to the Alzheimer's Association, more than 5.3 million Americans now suffer from the neurodegenerative illness, and it is the seventh leading cause of death. There is no effective treatment for Alzheimer's, and its origins remain unknown. For decades, research has focused on a buildup of amyloid beta plaques in the brain, but whether these deposits are a cause of the disease or merely a neutral artifact has remained unclear.

The new study looked at a lesser-known factor, the more mobile abeta oligomers that can form in brain tissue. In their research, Gandy's team first developed mice that only form abeta oligomers in their brains, and not amyloid plaques.

Based on the results of tests gauging spatial learning and memory, these mice were found to be impaired by Alzheimer's-like symptoms.

Next the researchers inserted a gene that would cause the mice to develop both oligomers and plaques.

Similar to the oligomer-only rodents, these mice "were still memory impaired, but no more memory impaired for having plaques superimposed on their oligomers," Gandy said.

Another result further strengthened the notion that oligomers were the prime cause of Alzheimer's in the mice.

"We tested the mice and they lost memory function, and when they died, we measured the oligomers in their brains," Gandy said. "Lo and behold, the degree of memory loss was proportional to the oligomer level," he said.

Gandy noted that PET scans are not able to detect oligomers in the human brain, but they do see amyloid plaques. This could help explain why recent trials of the experimental Alzheimer's drug bapineuzumab showed a reduction in plaques, but no improvement in patients' cognitive function, Gandy said.

Bapineuzumab is targeted to amyloid plaques. Whether the drug also affected the oligomers is not known, Gandy said, because the PET scans could not see them. "We don't even know whether bapineuzumab 'sees' them," he said.

The new study could help change the focus of ongoing research. "Our new 'oligomer only' mice may enable the development of imaging agents and drugs that lower oligomer levels without having plaques around to muddy the picture," Gandy said.

Researchers have long been trying to figure out the stages that lead up to plaques and tangles, Carrillo noted. "We [now] know that plaques and tangles are really the end stage of this disease," she said.

Oligomers are "toxic clumps" that could be the cause of Alzheimer's disease, Carrillo said. This study confirms for the first time that these toxic clumps are a cause of memory problems, she said.

Carrillo noted that these results also confirm that the disease starts developing 10 to 15 years before it is diagnosed. This understanding could lead to new ways of diagnosing and treating the illness, she added.

"Perhaps future therapeutics attacking oligomers instead of plaques would be a strategy," Carrillo said.

One expert did have some reservations about that possibility, however.

"The larger unresolved issue is how these oligomers relate to people where plaques accumulate many years prior to disease onset," said Greg M. Cole, professor of medicine and neurology and associate director of the UCLA Alzheimer's Center. "One would expect the little oligomer aggregates to arise prior to the bigger plaque aggregates, that is, decades before important memory problems [surface]."

That could mean that "targeting oligomers may work best for prevention," rather than the treatment of existing disease, he said. "Ongoing efforts to track and specifically target the oligomers in clinical trials with memory deficit patients should soon tell us how much good we can do hitting the oligomers. It may be a huge success or too little, too late."

More information

For more information on Alzheimer's disease, visit the Alzheimer's Association.

SOURCES: Sam Gandy, M.D., Ph.D., professor, neurology and psychiatry, associate director, Alzheimer's Disease Research Center, Mount Sinai School of Medicine, New York City; Greg M. Cole, Ph.D., professor of medicine and neurology, associate director, Alzheimer's Center, University of California, Los Angeles; Maria Carrillo, Ph.D., senior director of medical and scientific relations, Alzheimer's Association; April 14, 2010, Annals of Neurology

Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Scientists Report Key Finding in Breast Cancer Research
2. Research findings underscore needed action to safeguard lungs of young cancer survivors
3. Finding Good Migraine Care a Headache for the Uninsured
4. ACS Webinar features tips for finding and building a career in public policy and chemical industry
5. Cosmetic and Plastic Surgery Web Site Announces Improvements to the Patient Process of Finding Cosmetic Doctors in Their Area
6. Cedars-Sinai Heart Institute physicians present findings at ACC scientific meeting
7. Research findings expected to ease treatment of low neutrophil counts in cancer patients
8. Aims to Reduce Obesity Levels Through Sports Participation by Finding Sports Partners/Players/Teams
9. UMass Lowell researchers findings suggest new ways to diagnose and treat Alzheimers
10. VARI findings may help patients with deadly kidney cancer
11. Researchers Who Discovered First Genes for Stuttering will Present Findings to the National Stuttering Association
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Final Cut Pro X users can now reveal the media of their split ...
(Date:6/27/2016)... ... 27, 2016 , ... A revolution is underway. Brooklyn-based ... experience for the millions of people who require these medical transport services annually. ... through the use of technology. Now, SmartEMS has put forth an industry-changing app ...
(Date:6/26/2016)... , ... June 26, 2016 , ... On June 10-11, ... of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, ... the city’s history as home to some of the world’s leading providers of cereal ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer ... through a fitness app. The fitness app plans to fix the two major problems leading ... a one size fits all type program , They don’t eliminate all the ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
Breaking Medicine Technology: